Publications

European journal of cancer (Oxford, England : 1990)

AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response.

25-06-2026

Journal of the National Cancer Institute

Prognostic dynamics of pathological complete response and ctDNA clearance after neoadjuvant/perioperative immunotherapy in cancer: a reconstructed individual patient analysis.

18-06-2026

Scientific reports

Explainable machine learning identifies features and thresholds predictive of immunotherapy response.

23-05-2026

European journal of cancer (Oxford, England : 1990)

From prediction to precision: Biomarker discovery and predictive modeling for personalized immune checkpoint blockade therapy.

15-05-2026

Journal for immunotherapy of cancer

Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?

13-05-2026

Journal of cancer survivorship : research and practice

Long-term cognitive function after treatment with immune checkpoint inhibition for melanoma.

05-05-2026

Annals of surgical oncology

ASO Visual Abstract: International Survey on Evidence for Index Lymph Node Surgery Following Neoadjuvant Systemic Therapy for Stage III Melanoma.

01-05-2026

Future oncology (London, England)

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.

01-04-2026

The Lancet. Oncology

Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial.

01-03-2026

Nature medicine

Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

01-03-2026

Annals of surgical oncology

International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma.

01-03-2026

Nature reviews. Immunology

Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape.

01-02-2026

Annals of oncology : official journal of the European Society for Medical Oncology

Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma.

01-02-2026

Immunity

Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity.

13-01-2026

Nature medicine

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

01-12-2025

Key Publication

JAMA oncology

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma.

01-12-2025

European journal of cancer (Oxford, England : 1990)

Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma.

17-11-2025

Nature medicine

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.

01-11-2025

Cancer research communications

Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.

01-11-2025

European journal of cancer (Oxford, England : 1990)

Cross-sectional study of long-term Health-Related Quality of Life in stage III melanoma patients receiving neo-adjuvant versus adjuvant immune checkpoint inhibitors.

16-10-2025

Applied clinical informatics

Development and Evaluation of a Web-Based Outcome Database for Advanced Melanoma with Rare BRAF Mutations.

01-10-2025

European journal of cancer (Oxford, England : 1990)

Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database.

01-10-2025

Communications medicine

Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma.

30-09-2025

European journal of cancer (Oxford, England : 1990)

The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma.

09-09-2025

British journal of cancer

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

01-07-2025

European journal of cancer (Oxford, England : 1990)

Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma - A Swedish retrospective real-world study (NEO-MEL).

25-06-2025

Cancer immunology, immunotherapy : CII

Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures.

25-06-2025

European journal of cancer (Oxford, England : 1990)

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.

18-06-2025

Clinical cancer research : an official journal of the American Association for Cancer Research

Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.

03-06-2025

European journal of cancer (Oxford, England : 1990)

Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial.

03-06-2025

British journal of cancer

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

01-06-2025

Nature cancer

The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types.

01-06-2025

Journal of cancer survivorship : research and practice

Return to work after neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients.

26-05-2025

European journal of cancer (Oxford, England : 1990)

Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].

05-02-2025

European journal of cancer (Oxford, England : 1990)

Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo.

01-01-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

01-01-2025

Cancer treatment reviews

Local administration of immunotherapy for patients with skin cancer: A systematic review.

01-12-2024

Immuno-oncology technology

Integrated noninvasive diagnostics for prediction of survival in immunotherapy.

01-12-2024

Cell host & microbe

Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients.

13-11-2024

JCI insight

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.

08-11-2024

The New England journal of medicine

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

07-11-2024

European journal of cancer (Oxford, England : 1990)

Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.

01-11-2024

European journal of cancer (Oxford, England : 1990)

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

01-11-2024

Nature medicine

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

01-11-2024

European journal of cancer (Oxford, England : 1990)

Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy.

01-11-2024

International journal of cancer

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.

15-10-2024

Cancer cell

Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8⁺ T cells.

09-09-2024

The Lancet. Oncology

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

01-09-2024

Journal of experimental & clinical cancer research : CR

Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy.

21-08-2024

European journal of cancer (Oxford, England : 1990)

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

01-08-2024

AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response.

Prognostic dynamics of pathological complete response and ctDNA clearance after neoadjuvant/perioperative immunotherapy in cancer: a reconstructed individual patient analysis.

Explainable machine learning identifies features and thresholds predictive of immunotherapy response.

From prediction to precision: Biomarker discovery and predictive modeling for personalized immune checkpoint blockade therapy.

Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?

Long-term cognitive function after treatment with immune checkpoint inhibition for melanoma.

ASO Visual Abstract: International Survey on Evidence for Index Lymph Node Surgery Following Neoadjuvant Systemic Therapy for Stage III Melanoma.

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.

Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial.

Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma.

Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape.

Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma.

Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity.

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma.

Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma.

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.

Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.

Cross-sectional study of long-term Health-Related Quality of Life in stage III melanoma patients receiving neo-adjuvant versus adjuvant immune checkpoint inhibitors.

Development and Evaluation of a Web-Based Outcome Database for Advanced Melanoma with Rare BRAF Mutations.

Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database.

Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma.

The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma.

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma - A Swedish retrospective real-world study (NEO-MEL).

Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures.

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.

Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.

Durable responses upon short-term addition of targeted therapy to anti-PD1 in advanced melanoma patients: 5-year progression-free and overall survival update of the IMPemBra trial.

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types.

Return to work after neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients.

Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].

Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo.

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Local administration of immunotherapy for patients with skin cancer: A systematic review.

Integrated noninvasive diagnostics for prediction of survival in immunotherapy.

Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients.

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy.

Adjuvant treatment with anti-PD-1 in acral melanoma: A nationwide study.

Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells.

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy.

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.

This site uses cookies

Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8⁺ T cells.